Generic Name and Formulations:
Hydrocortisone probutate 0.1%; crm.
Indications for PANDEL:
≥18yrs: apply thin film to affected area 1–2 times daily. Discontinue when control is achieved. Reassess if no improvement within 2 weeks.
<18yrs: not established.
Avoid near or around eyes, face, underarms, groin areas. Occlude only if necessary. Not for diaper dermatitis; do not use in diaper area. Evaluate for HPA axis suppression periodically (esp. in prolonged use, application to large surface area, use of occlusive dressings, impaired skin, or in children); discontinue or reduce dose or potency if occurs. Hepatic impairment. Diabetes. Discontinue if irritation develops. Avoid abrupt cessation. Pregnancy. Nursing mothers: use on the smallest area of skin for the shortest duration.
Burning, stinging, rash, redness, itching, paresthesia, contact dermatitis; HPA axis suppression (esp. in children), Cushing's syndrome, hyperglycemia, skin atrophy, secondary infections.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma